Multiple System Atrophy Market Trends

Growth Drivers

• Quality optimization and cost-effective interventions: Quality-of-care strategies are effectively reducing the economic load of MSA, while uplifting results, which is a suitable driver for uplifting the multiple system atrophy market globally. According to an article published by NLM in March 2024, the prevalence of MSA range from 1.9 in Gironde, 4.4 in London, and 3.4 in Iceland per 100,000 population. Therefore, to combat the spread, neuroimaging and radiotracer-based functional imaging technologies can readily support the MSA diagnosis, thus suitable for boosting the market’s development globally.
• An increase in disease occurrence and aging population: The international market’s patient pool is highly driven by advanced diagnostics and aging demographics. As per the August 2024 NLM article, the most common type of symptoms associated with the disease include, 96.7% of urinary dysfunction, followed by 43.3% of gait ataxia, and 33.3% of orthostatic symptoms. Therefore, to reduce these symptoms, artificial intelligence-based diagnostic tools, such as Lundbeck’s algorithm, have readily diminished misdiagnosis rates, thereby making it suitable for the market’s growth.
• Resilience and API sourcing in supply chain: The presence of administrative and geopolitical challenges is effectively reshaping the supply chain system in the market internationally. Besides, the FDA has denoted an increase in APIs for MSA, which originates from Europe and North America, thereby creating vulnerabilities to enhance manufacturing and production expenses. However, organizations are positively impacting suppliers, with the CDMO in South Korea providing global neurology APIs, while Teva in Israel is readily leveraging continuous manufacturing to diminish lead times.

Neurological Disease Risk Factors Boosting the Market (2023)

Source: NLM

Challenges

• Fragmentation in administrative policies: The lack of global regulatory harmonization has created expensive delays for drug producers in the multiple system atrophy market. For instance, expanded requirements have increased to manufacturing reforms, with the newest Annex 1 policies having imposed high compliance costs in Europe, especially for sterile injectable in 2023. However, developing countries have readily compounded this complexity, with the CDSCO in India constituting demanding domestic batch evaluation for imports, thus creating a huge bottleneck and effectively combating this risk to uplift the market’s exposure internationally.
• Limitation in payer coverage for public healthcare: Public payers proactively rationed MSA-specific treatments due to stringent budget allocations, which has caused a hindrance in the multiple system atrophy market. Besides, Medicaid services in the U.S. has effectively covered an estimated coverage of the FDA-based MSA therapies, thus readily focusing on affordable and prioritized generics, which includes levodopa, compared to the newest biologics. However, Neurocrine Biosciences combated this issue by integrating outcome-specific rebates by connecting payments to evaluative symptom enhancement, along with expanded coverage in half of Medicaid plans.